CytRx Corp. (US OTC:CYTR)

About the company

CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

4

CEO

Steven A. Kriegsman

Exchange

US OTC

Website

http://www.cytrx.com

$0.00M

Total Revenue

4

Employees

$22.11M

Market Capitalization

-3.19

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 11671.80 1376.00 4.98 18.40 43.06
Catalent, Inc. CTLT 10932.13 2872.00 5.49 104.81 3.63
Perrigo Co. Plc PRGO 7571.99 4837.00 1.30 51.65 3.02
Bausch Health Cos., Inc. BHC 6456.37 8597.00 9.01 -3.41 -21.96
Jazz Pharmaceuticals Plc JAZZ 6247.77 2188.00 2.16 22.84 12.81
United Therapeutics Corp. UTHR 5203.00 1443.00 1.81 10.04 36.59
MyoKardia, Inc. MYOK 4316.64 34.00 12.55 -13.92 -201.73
Axsome Therapeutics, Inc. AXSM 2672.60 None 18.14 -29.71 None
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
Pacira Biosciences, Inc. PCRX 2231.88 435.00 5.98 -5314.00 -0.02
SAGE Therapeutics, Inc. SAGE 2162.16 9.00 2.54 -3.34 -413.06
Corcept Therapeutics, Inc. CORT 2084.98 335.00 4.79 19.64 31.64
Revolution Medicines, Inc. RVMD 1920.45 48.00 4.98 -27.12 -146.29
Prestige Consumer Healthcare, Inc. PBH 1881.39 963.00 1.58 13.27 14.77
Madrigal Pharmaceuticals, Inc. MDGL 1765.35 0.00 4.71 -17.28 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1620.24 440.00 -22.93 19.11 19.14
Innoviva, Inc. INVA 1574.09 285.00 3.72 8.15 66.41
Intercept Pharmaceuticals, Inc. ICPT 1476.16 272.00 -43.93 -4.30 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Zogenix, Inc. ZGNX 1308.15 5.00 3.57 -3.08 -241.62
Supernus Pharmaceuticals, Inc. SUPN 1254.96 402.00 1.99 10.76 28.90
Theravance Biopharma, Inc. TBPH 1196.43 88.00 -8.40 -4.85 -280.80
Revance Therapeutics, Inc. RVNC 1181.11 0.00 4.66 -6.33 41.82
Amphastar Pharmaceuticals, Inc. AMPH 1088.78 327.00 2.72 21.37 15.90
Endo International Plc ENDP 800.28 3014.00 -1.09 -2.85 -9.09
BellRing Brands, Inc. BRBR 764.79 954.00 -0.41 5.80 13.98
Aerie Pharmaceuticals, Inc. AERI 678.96 79.00 5.39 -3.35 -252.92
Assembly Biosciences, Inc. ASMB 676.28 16.00 3.03 -6.80 -601.75
Eagle Pharmaceuticals, Inc. EGRX 671.72 192.00 3.61 266.56 1.29
Collegium Pharmaceutical, Inc. COLL 590.58 299.00 4.23 -45.71 -4.21
Anika Therapeutics, Inc. ANIK 539.98 125.00 1.87 19.48 22.73
Catalyst Pharmaceuticals, Inc. CPRX 487.92 119.00 4.75 11.12 36.09
Intersect ENT, Inc. XENT 411.20 102.00 3.88 -8.24 -48.61
BioDelivery Sciences International, Inc. BDSI 405.26 130.00 5.80 -55.06 -5.01
ANI Pharmaceuticals, Inc. ANIP 391.32 203.00 2.00 -250.85 -0.67
MEI Pharma, Inc. MEIP 356.90 5.00 6.14 -9.15 -539.48
Albireo Pharma, Inc. ALBO 344.37 11.00 3.50 -4.51 -730.55
Mallinckrodt Plc MNK 233.52 3037.00 0.12 -0.19 -39.56
Marinus Pharmaceuticals, Inc. MRNS 168.21 0.00 6.51 -2.50 None
Agile Therapeutics, Inc. AGRX 164.02 None 2.67 -7.94 None
Zynerba Pharmaceuticals, Inc. ZYNE 144.90 0.00 2.38 -4.04 -699.94
Cerecor, Inc. CERC 119.60 7.00 7.65 -5.31 -429.22
Ampio Pharmaceuticals, Inc. AMPE 97.81 1.00 68.40 -5.26 None
AcelRx Pharmaceuticals, Inc. ACRX 94.40 2.00 -1.74 -1.69 -644.25
Evoke Pharma, Inc. EVOK 84.96 None 29.50 -12.64 None
Adamas Pharmaceuticals, Inc. ADMS 70.28 57.00 -4.48 -0.76 -160.44
CTI BioPharma Corp. CTIC 67.85 3.00 3.03 -1.64 -111.83
Aclaris Therapeutics, Inc. ACRS 67.65 4.00 1.19 -0.49 None
Oramed Pharmaceuticals, Inc. ORMP 62.64 3.00 5.04 -4.90 -464.15
Cassava Sciences, Inc. SAVA 56.81 41.00 2.99 -12.46 76.71
Cumberland Pharmaceuticals, Inc. CPIX 49.95 47.00 1.02 -11.10 -9.59
SCYNEXIS, Inc. SCYX 49.93 0.00 10.49 -1.29 -30.84
Natural Alternatives International, Inc. NAII 48.37 114.00 0.66 -12.80 -3.19
Lipocine, Inc. LPCN 37.80 0.00 9.00 -2.52 None
IsoRay, Inc. ISR 37.77 9.00 7.05 -11.27 -36.08
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 34.25 65.00 -2.63 -1.96 -26.74
PLx Pharma, Inc. PLXP 27.99 0.00 -2.68 -2.96 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 19.61 3.00 2.44 -1.66 -264.21
Regulus Therapeutics, Inc. RGLS 14.91 0.00 1.31 -0.70 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.60 8.00 0.67 -0.15 -798.18
Intec Pharma Ltd. NTEC 10.87 None 1.40 -0.25 None
VIVUS, Inc. VVUS 8.91 73.00 -0.20 -0.30 -39.28
Sonoma Pharmaceuticals, Inc. SNOA 7.12 19.00 1.13 -2.28 -25.58
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
Hepion Pharmaceuticals, Inc. HEPA 5.42 None 1.69 -0.46 None
Tonix Pharmaceuticals Holding Corp. TNXP 4.36 None 1.09 -0.09 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease

2d ago, source: PR Newswire

PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally ...

CytRx up ~4% as Orphazyme reports positive outcome from mid-stage study of Arimoclomol in Gaucher Disease

2d ago, source: Seeking Alpha

CytRx (OTCQB:CYTR +4.3%) highlights that Orphayzme announces topline results of Phase 2 dose-finding study with arimoclomol in Gaucher disease (buildup of certain fatty substances in certain organs); ...

CytRx Corp.

16d ago, source: MarketWatch

Founder of Kriegsman Capital Group LLC, Steven A. Kriegsman is Chairman & Chief Executive Officer at CytRx Corp. In his past career Mr. Kriegsman was Chairman at Kriegsman Capital Group LLC ...

CytRx: 2Q Earnings Snapshot

16d ago, source: Yahoo! News

LOS ANGELES (AP) _ CytRx Corp. (CYTR) on Monday reported a loss of $3 million in its second quarter. The Los Angeles-based company said it had a loss of 10 cents per share. The company's shares closed ...

CytRx Price to Book Value:

6d ago, source: YCharts

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that ...

CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin

1mon ago, source: PR Newswire

LOS ANGELES, May 21, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.